The world\'s first homozygous parthenogenetic stem cell lines that can provide therapeutic cells with the potential to be transplanted into hundreds of millions of individuals of differing ages and racial backgrounds with minimal risk of immune rejection
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of International Stem Cell (OTCQB: ISCO) (aka ISCO) plus 4816 other startups.